Sumitomo Pharma Co., Ltd. Logo

Sumitomo Pharma Co., Ltd.

R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.

4506 | T

Overview

Corporate Details

ISIN(s):
JP3495000006
LEI:
Country:
Japan
Address:
大阪市中央区道修町2丁目6番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sumitomo Pharma Co., Ltd. is a research and development-oriented pharmaceutical company focused on creating innovative medicines and healthcare solutions. The company concentrates its R&D and commercial activities in the therapeutic areas of oncology, psychiatry, and neurology. It develops treatments across various modalities, including small molecules, regenerative medicine, and cell therapy. Sumitomo Pharma operates with global business platforms, with a strategic focus on Japan and the United States as its primary markets. The company's mission is to contribute to the betterment of healthcare and fuller lives for people worldwide by translating scientific innovation into real-world solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 08:19
Registration Form
確認書
Japanese 8.7 KB
2025-11-04 08:13
Interim Report
半期報告書-第206期(2025/04/01-2025/09/30)
Japanese 319.2 KB
2025-10-31 08:39
M&A Activity
訂正臨時報告書
Japanese 41.0 KB
2025-06-27 09:05
Post-Annual General Meeting Information
臨時報告書
Japanese 29.6 KB
2025-06-26 09:39
Registration Form
確認書
Japanese 8.7 KB
2025-06-26 09:36
Governance Information
内部統制報告書-第205期(2024/04/01-2025/03/31)
Japanese 24.0 KB
2025-06-26 09:31
Annual Report
有価証券報告書-第205期(2024/04/01-2025/03/31)
Japanese 2.1 MB
2025-05-30 09:41
M&A Activity
訂正臨時報告書
Japanese 40.7 KB
2025-05-14 09:18
M&A Activity
訂正臨時報告書
Japanese 36.6 KB
2025-04-28 10:06
Regulatory News Service
訂正臨時報告書
Japanese 24.3 KB
2025-04-28 10:03
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2025-04-03 09:39
M&A Activity
臨時報告書
Japanese 41.7 KB
2025-01-31 08:11
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-12-19 07:19
Regulatory News Service
臨時報告書
Japanese 19.2 KB
2024-11-01 03:30
Interim Report
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Sumitomo Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sumitomo Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sumitomo Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.